CAJ | 학술논문

目的：研究初治肺结核患者应用草分枝杆菌F．U．36辅治的效果及其对免疫功能的影响。方法选择2013年5月—2014年7月收治的肺结核患者86例，按照入院顺序将患者分为观察组（43例）和对照组（43例）。所有患者给予利福平、异烟肼、己胺丁醇等抗结核药物，观察组患者在此基础之上，给予草分枝杆菌F．U．36。观察2组患者治疗后的临床疗效，主要包括症状改善、肺CT改善以及复发情况，观察2组患者治疗前和治疗18周后的免疫功能变化。结果观察组患者的症状总改善率（97．67％）显著高于对照组（83．72％），差异具有统计学意义（χ2＝11．900， P ＜0．01）；观察组患者肺部CT病灶总好转率（97．68％）显著高于对照组（81．39％），差异具有统计学意义（χ2＝11．179， P ＜0．01）；治疗后，观察组患者的 IgG（8．63±3．76）g／L，IgM（1．13±0．53）g／L，CD4＋（32．10±13．20）％，CD8＋（32．30±8．20）％均显著优于对照组的（6．64±3．25） g／L、（0．91±0．47）） g／L、（38．60±7．60）％、（27．70±5．60）％，差异均有统计学意义（ t ＝2．626、2．037、2．798、3．038， P ＜0．05）；观察组中无复发患者，对照组出现病情复发8例（18．6％），差异具有统计学意义（χ2＝8．821， P ＜0．05）。结论初治肺结核患者辅以草分枝杆菌F．U．36治疗，能够明显改善患者的症状、病灶和免疫功能，值得广泛推广使用。
목적：연구초치폐결핵환자응용초분지간균F．U．36보치적효과급기대면역공능적영향。방법선택2013년5월—2014년7월수치적폐결핵환자86례，안조입원순서장환자분위관찰조（43례）화대조조（43례）。소유환자급여리복평、이연정、기알정순등항결핵약물，관찰조환자재차기출지상，급여초분지간균F．U．36。관찰2조환자치료후적림상료효，주요포괄증상개선、폐CT개선이급복발정황，관찰2조환자치료전화치료18주후적면역공능변화。결과관찰조환자적증상총개선솔（97．67％）현저고우대조조（83．72％），차이구유통계학의의（χ2＝11．900， P ＜0．01）；관찰조환자폐부CT병조총호전솔（97．68％）현저고우대조조（81．39％），차이구유통계학의의（χ2＝11．179， P ＜0．01）；치료후，관찰조환자적 IgG（8．63±3．76）g／L，IgM（1．13±0．53）g／L，CD4＋（32．10±13．20）％，CD8＋（32．30±8．20）％균현저우우대조조적（6．64±3．25） g／L、（0．91±0．47）） g／L、（38．60±7．60）％、（27．70±5．60）％，차이균유통계학의의（ t ＝2．626、2．037、2．798、3．038， P ＜0．05）；관찰조중무복발환자，대조조출현병정복발8례（18．6％），차이구유통계학의의（χ2＝8．821， P ＜0．05）。결론초치폐결핵환자보이초분지간균F．U．36치료，능구명현개선환자적증상、병조화면역공능，치득엄범추엄사용。
Objective To investigate the effect and immune function changes of using mycobacterium F ..U.36 in treating patients with pulmonary tuberculosis .Methods From May 2013 to July 2014 , 86 cases of tuberculosis patients were enrolled, the patients were divided according to the order of admission into observation group (43 cases) and control group (43 cases).All patients were treated with rifampin(0.45 g), isoniazid(0.3 g), and amine butanol(0.75 g),once a day, observation group patients also received mycobacterium F .U.36(1.72 μg/ml).After treatment’s clinical efficacy, including symptoms , improvement of lung CT and recurrence were observed in all patients , changes in immune function in two groups of patients before treatment and after 18 weeks of treatment were observed .Results The total symptom improvement rate of the observation group (97.67%) was significantly higher than control group (83.72%), the difference were statistically signifi-cant (χ2 =11.900, P <0.01); after treatment, observation group’s CT lung lesions overall improvement rate (97.68%) was significantly higher than control group (81.39%), the difference was statistically significant (χ2 =11.179, P <0.05);after treatment, observation group’s IgG (8.63 ±3.76) g /L, IgM (1.13 ±0.53) g /L, CD4+(32.10 ±13.20)%, CD8+(32.30 ±8.20)%was significantly better than the control group ’s (6.64 ±3.25) g /L, (0.91 ±0.47)) g /L, (38.60 ±7.60)%, (27.70 ±5.60)%, the difference was statistically significant ( t =2.626, t =2.0375, t =2.798, t =3.038, P <0.05); no recurrence were found in the observation group , and control group had a recurrence of 8 cases (18.6%), the difference was statistically significant (χ2 =8.821, P <0.05).Conclusion For the initial treatment of tu-berculosis patients , mycobacteriumphlei F .U.36 can significantly improve symptoms , lesions and immune function , it is worth widely used.